Featured Research

from universities, journals, and other organizations

More pills, less quality of life for kidney patients

Date:
May 12, 2009
Source:
American Society of Nephrology
Summary:
The more pills a dialysis patients takes, the worse their health-related quality of life, according to a new study. The findings indicate that increasing the number of medications to control patients' disease may interfere with their ability to enjoy normal activities. The new study finds dialysis patients take an average of 19 pills a day.

The more pills a dialysis patients takes, the worse their health-related quality of life, according to a new study. The findings indicate that increasing the number of medications to control patients' disease may interfere with their ability to enjoy normal activities.

Kidney disease patients undergoing dialysis must take more pills than most patients with other chronic diseases. While these medications are important for controlling patients' disease, at some point taking too many pills (with their ensuing side effects) may negatively affect patients' health-related quality of life, or their perceived physical and mental health.

Rajnish Mehrotra, MD and Yi-Wen Chiu, MD (Los Angeles Biomedical Research Institute), and their colleagues conducted a study to see if "pill burden" affects dialysis patients' health-related quality of life. They studied 233 chronic dialysis patients from three clinics in different geographic areas in the United States.

The investigators found that patients took an average of 19 pills a day and that a quarter of the patients took more than 25 pills a day. Patients with a high pill burden had lower perceived physical health. Medications called phosphate binders, which control the level of phosphorus in the blood, accounted for about half of the daily pill burden. Sixty-two percent of the patients did not take these medications as directed. The more phosphate binders a patient was prescribed, the less likely they were to take their medications as directed and the less likely they were to have their blood phosphorus levels under control. These findings indicate that increasing the number of prescribed pills does not seem to improve control of phosphorus levels and may come at the cost of poorer health-related quality of life.

The authors note that any attempts to tackle dialysis patients' pill burden must address the number of phosphate binders a patient is prescribed on a daily basis.

Dr. Mehrotra has received grant support and serves as a consultant for Shire Pharmaceuticals, the makers of lanthanum carbonate. This study was funded by a grant from Shire Pharmaceuticals.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. Clinical Journal of the American Society Nephrology, May 7, 2009 DOI: 10.2215/CJN.00290109

Cite This Page:

American Society of Nephrology. "More pills, less quality of life for kidney patients." ScienceDaily. ScienceDaily, 12 May 2009. <www.sciencedaily.com/releases/2009/05/090507173659.htm>.
American Society of Nephrology. (2009, May 12). More pills, less quality of life for kidney patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/05/090507173659.htm
American Society of Nephrology. "More pills, less quality of life for kidney patients." ScienceDaily. www.sciencedaily.com/releases/2009/05/090507173659.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins